Disease · MONDO_0019127

polymyositis

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. polymyositis. Diseases, record MONDO_0019127. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0019127

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: polymyositis; Open Targets
Open Targets ID: MONDO_0019127; Open Targets
Other names: Myositis, Multiple, PM, Polymyositis (disorder), Polymyositis Ossificans, Polymyositis, Idiopathic, multiple myositis; Open Targets
Disease Ontology: DOID:0080745; Disease Ontology
MeSH: D017285; MeSH
NCI Thesaurus: C26925; NCI Thesaurus
Orphanet: ORPHA:732; Orphanet
Highest stage of its drugs: Approval, for 2 of its 28 drugs, from DailyMed; Open Targets

Drugs28

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
PREDNISONE	CHEMBL635	Small molecule	Approval	DailyMed	2	1	1	Drugs and targets
CORTISONE ACETATE	CHEMBL1650	Small molecule	Approval	DailyMed	2	0	0	Drugs and targets
DAZUKIBART	CHEMBL4297808	Antibody	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
ANIFROLUMAB	CHEMBL2364653	Antibody	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
METHOTREXATE	CHEMBL34259	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
USTEKINUMAB	CHEMBL1201835	Antibody	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
INFLIXIMAB	CHEMBL1201581	Antibody	Phase 2/3	ClinicalTrials.gov	2	2	2	Drugs and targets
TACROLIMUS	CHEMBL3989887	Small molecule	Phase 2/3	ClinicalTrials.gov	2	2	2	Drugs and targets
ANAKINRA	CHEMBL1201570	Protein	Phase 2/3	ClinicalTrials.gov	1	1	1	Drugs and targets
BELIMUMAB	CHEMBL1789843	Antibody	Phase 2/3	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 28

See all 28 drugs

Targets40

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
NR3C1	Glucocorticoid receptor	3	Glucocorticoid receptor agonist	Approval	https://conductscience.org/library/genes/2908	Drugs and targets
CD80	T-lymphocyte activation antigen CD80	1	T-lymphocyte activation antigen CD80 inhibitor	Phase 2	https://conductscience.org/library/genes/941	Drugs and targets
CD86	T-lymphocyte activation antigen CD86	1	T-lymphocyte activation antigen CD86 inhibitor	Phase 2	https://conductscience.org/library/genes/942	Drugs and targets
DHFR	Dihydrofolate reductase	1	Dihydrofolate reductase inhibitor	Phase 3	https://conductscience.org/library/genes/1719	Drugs and targets
FCGRT	IgG receptor FcRn large subunit p51	1	IgG receptor FcRn large subunit p51 antagonist	Phase 2/3	https://conductscience.org/library/genes/2217	Drugs and targets
FKBP1A	Peptidyl-prolyl cis-trans isomerase FKBP1A	1	FK506-binding protein 1A inhibitor	Phase 2/3	https://conductscience.org/library/genes/2280	Drugs and targets
HMGCR	3-hydroxy-3-methylglutaryl-coenzyme A reductase	1	HMG-CoA reductase inhibitor	Unknown	https://conductscience.org/library/genes/3156	Drugs and targets
IFNA1	Interferon alpha	1	Interferon alpha inhibitor	Phase 2	https://conductscience.org/library/genes/3439	Drugs and targets
IFNA10	Interferon alpha	1	Interferon alpha inhibitor	Phase 2	https://conductscience.org/library/genes/3446	Drugs and targets
IFNA13	Interferon alpha	1	Interferon alpha inhibitor	Phase 2	https://conductscience.org/library/genes/3447	Drugs and targets

1 to 10 of 40

See all 40 targets

Trials30

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00106184	Rituximab for the Treatment of Refractory Adult and Juvenile Dermatomyositis (DM) and Adult Polymyositis (PM)	Phase 2	200	2015-03-04	Myositis, Dermatomyositis, Polymyositis, Juvenile Dermatomyositis	RITUXIMAB	Its record names the disease	ClinicalTrials.gov
NCT00979654	A Study to Evaluate the Long-Term Safety of MEDI-545 in Adult Participants With Systemic Lupus Erythematosus or Myositis	Phase 2	118	2016-08-23	Systemic Lupus Erythematosus	SIFALIMUMAB	Its record names the disease	ClinicalTrials.gov
NCT03981744	A Study of Ustekinumab in Participants With Active Polymyositis and Dermatomyositis Who Have Not Adequately Responded to One or More Standard-of-care Treatments	Phase 3	51	2024-05-13	Polymyositis, Dermatomyositis	USTEKINUMAB	Its record names the disease	ClinicalTrials.gov
NCT02043548	Tocilizumab in the Treatment of Refractory Polymyositis and Dermatomyositis	Phase 2	36	2020-10-30	Dermatomyositis, Polymyositis	TOCILIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT00651040	Combined Treatment of Methotrexate + Glucocorticoids Versus Glucocorticoids Alone in Patients With PM and DM	Phase 3	31	2016-05-12	Polymyositis, Dermatomyositis	METHOTREXATE, PREDNISONE	Its record names the disease	ClinicalTrials.gov
NCT00504348	Investigation in Myositis-associated Pneumonitis of Prednisolone And Concomitant Tacrolimus	Phase 2/3	25	2020-03-24	Interstitial Pneumonitis, Polymyositis, Dermatomyositis	PREDNISOLONE, TACROLIMUS	Its record names the disease	ClinicalTrials.gov
NCT04033926	A Phase 2 Study of KZR-616 to Evaluate Safety and Efficacy in Patients With Active Polymyositis or Dermatomyositis	Phase 2	25	2024-01-03	Polymyositis, Dermatomyositis	ZETOMIPZOMIB	Its record names the disease	ClinicalTrials.gov
NCT01148810	Efficacy and Tolerability of BAF312 in Patients With Polymyositis and Dermatomyositis	Phase 2	18	2019-04-25	Polymyositis, Dermatomyositis	SIPONIMOD	Its record names the disease	ClinicalTrials.gov
NCT04628936	Open-label Extension to the Phase 2 Crossover Study (PRESIDIO) Evaluating KZR-616 in Patients With PM and DM.	Phase 2	18	2024-06-05	Polymyositis, Dermatomyositis	ZETOMIPZOMIB	Its record names the disease	ClinicalTrials.gov
NCT02347891	Belimumab in Idiopathic Inflammatory Myositis	Phase 2/3	17	2024-02-09	Myositis	BELIMUMAB	Its record names the disease	ClinicalTrials.gov

1 to 10 of 30

See all 30 trials

Comparisons in its trials9

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Treatment Group A (Rituximab Wks 0 and 1) vs Treatment Group B (Rituximab Wks 8 and 9): Response Rates (Proportion of Improved Patients) Between Groups A (Rituximab Wks 0 and 1) and B (Rituximab Wks 8 and 9) at Week 8	14 of 96	21 of 104	200	NCT00106184	Trial comparisons
Treatment Group A (Rituximab Wks 0 and 1) vs Treatment Group B (Rituximab Wks 8 and 9): 20% Improvement in Manual Muscle Testing (MMT) Over Baseline on Two Consecutive Time Points (Muscle is the Primary Organ of Involvement, and MMT is the One Objective Measurement of the Definition of Improvement [DOI])	14 of 96	21 of 104	200	NCT00106184	Trial comparisons
Treatment Group A vs Treatment Group B: serious adverse events	24 of 96	41 of 104	200	NCT00106184	Trial comparisons
Group A: Tocilizumab vs Group B: Placebo: deaths from any cause	0 of 18	0 of 18	36	NCT02043548	Trial comparisons
Group A: Tocilizumab vs Group B: Placebo: serious adverse events	1 of 18	0 of 18	36	NCT02043548	Trial comparisons
1 Prednison vs 2 Prednison Methotrexate: serious adverse events	4 of 16	5 of 15	31	NCT00651040	Trial comparisons
BAF312/BAF312 vs Placebo/BAF312: deaths from any cause	0 of 16	0 of 10	26	NCT01148810	Trial comparisons
BAF312/BAF312 vs Placebo/BAF312: serious adverse events	0 of 16	3 of 10	26	NCT01148810	Trial comparisons
BAF312/BAF312 vs Placebo/BAF312: Number of Participants Who Responded to BAF312	4 of 8	1 of 8	16	NCT01148810	Trial comparisons

Papers from its trials12

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
31539061	RESULT	1	PubMed
23124935	RESULT	1	PubMed
327194	RESULT	1	PubMed
40297385	DERIVED	1	PubMed
37941470	DERIVED	1	PubMed
37652554	DERIVED	1	PubMed
37326854	DERIVED	1	PubMed
35428708	DERIVED	1	PubMed
33852146	DERIVED	1	PubMed
29237618	DERIVED	1	PubMed

1 to 10 of 12

See all 12 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0019127

GET https://conductscience.org/api/diseases/v1/MONDO_0019127/drugs?page=2

API reference For AI assistants